Copy to clipboard 
Evonik opened its largest center for medical device applications in Shanghai, serving the entire Asian market. This facility specializes in the research, development and processing of semi-finished components for bioresorbable medical devices, aiming to support customers in overcoming challenges related to the innovation of high-quality medical devices.
“Our next-generation biomaterials are enabling our customers to innovate new medical technologies that create life beyond limits. The latest addition to our global technical service network can help more customers across Asia in reducing complexity, accelerating time to market, and improving medical device performance,” says Yann d’Hervé, head of Evonik Health Care.
The Evonik Shanghai Medical Device Center offers comprehensive one-stop solutions that range from concept development, material selection and customization, prototyping and processing, analytical services, quality and regulatory documentation, to manufacturing semi-finished products and components in an ISO class 7 cleanroom environment. The center converts Evonik’s standard and customized biomaterials into various types of semi-finished components. These components are designed with specific properties, including bioresorbability, low-friction, antithrombotic and antibacterial characteristics. Medical device manufacturers can then further process them to meet specific requirements for diverse applications in orthopedics, sports medicine, etc.
“The innovation of high-end medical devices plays a key role in the government’s Healthy China 2030 initiative. Manufacturers are increasingly pursuing competitive raw materials and service solutions to differentiate themselves in the world’s second-largest medical device market,” said Fuliang Xia, President of Evonik Greater China. “Our new center is strategically aligned with these urgent market demands and contributes to the acceleration of industrial upgrading.”
Evonik is a global innovation hub for next-generation biomaterials, encompassing bioresorbable polymers, surface modification technology, biosynthetic cellulose and non-animal-derived recombinant collagen platforms.
Source: Evonik
